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Abstract: Frontotemporal Lobar Degeneration (FTLD) encompasses certain related neurodegenerative disorders
which alter personality and cognition. Heterogeneous ribonuclear proteins (hnRNPs) maintain RNA metabolism and
changes in their function may underpin the pathogenesis of FTLD. Immunostaining for hnRNP E2 was performed
on sections of frontal and temporal cortex with hippocampus from 80 patients with FTLD, stratified by pathology
into FTLD-tau and FTLD-TDP type A, B and C subtypes, and by genetics into patients with C9orf72 expansions,
MAPT or GRN mutations, or those with no known mutation, and on 10 healthy controls. Semi-quantitative analysis
assessed hnRNP staining in frontal and temporal cortex, and in dentate gyrus (DG) of hippocampus, in the different
pathology and genetic groups. We find that hnRNP E2 immunostaining detects the TDP-43 positive dystrophic
neurites (DN) within frontal and temporal cortex, and the neuronal cytoplasmic inclusions (NCI) seen in DG granule
cells, characteristic of patients with Semantic Dementia (SD) and type C TDP-43 pathology, but did not detect TDP-43
or tau inclusions in any of the other pathological or genetic variants of FTLD. Double immunofluorescence for hnRNP
E2 and TDP-43 showed most TDP-43 immunopositive DN to contain hnRNP E2. Present findings indicate an
association between TDP-43 and hnRNP E2 which might underlie the pathogenetic mechanism of this form of FTLD.
Introduction
Frontotemporal Lobar Degeneration (FTLD) is a clinically,
pathologically and genetically heterogeneous disorder
affecting principally the frontal and temporal lobes of the
brain. Three major clinical syndromes are recognised [34].
One syndrome, behavioural variant frontotemporal de-
mentia (bvFTD), is characterised by changes in behaviour
and personality and accounts for around 75% of all cases
of FTLD, whereas the other two syndromes are disorders
of language [34]. Semantic dementia (SD) (also known as
semantic variant of primary progressive aphasia (svPPA))
is a disorder characterized by loss of conceptual know-
ledge of the meaning of words and objects [14, 34],
whereas Progressive Non-Fluent Aphasia (PNFA) (also
known as nfvPPA) is represented by an inability to con-
struct language such that speech becomes hesitant and
stuttering, becoming grammatically and contextually
incorrect [14, 34]. The amyotrophic lateral sclerosis (ALS)
form of motor neurone disease (MND) is seen in about
15% of patients with bvFTD, but is only rarely combined
with either SD or PNFA [32].
Three different pathologies, characterised by abnormal
neuronal, and sometimes glial, accumulations of aggregated
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proteins, are seen. Neuronal intracytoplasmic inclu-
sions (NCI), composed of the microtubule associated
protein tau, occur in about 45% cases as neurofibrillary
tangle-like structures, or more rounded inclusions
known as Pick bodies [33] and termed FTLD-tau [19].
The RNA and DNA binding protein, TDP-43, is present
within NCI, neuritic processes (dystrophic neurites,
DN) or neuronal intranuclear inclusions (NII) in about
50% of cases [2, 7, 26]. The relative proportions of NCI,
DN and NII provide a neuropathological classification
of FTLD-TDP subtypes [19]. FTLD-TDP subtype A is
applied when NCI and short DN are both commonly
present, mostly in outer cortical laminae, type B when
NCI present throughout all cortical layers numerically
predominate over DN, type C when long thick DN are
present throughout all cortical layers and predominate
over NCI and type D when NII are most common type of
pathological change [19]. Most of the remaining 5% cases
show NCI composed of the protein, Fused in Sarcoma
(FUS), and are known as FTLD-FUS [19].
TDP-43 and FUS are heterogeneous nuclear riboproteins
(hnRNP) [5, 30] and serve as RNA-splicing and transcrip-
tion regulators, shuttling between nucleus and cytoplasm,
thereby controlling cellular levels of protein synthesis. In
the nucleus, TDP-43 binding encourages RNA stability,
whereas in the cytoplasm it associates with stress granules
and non-coding RNAs for post-transcriptional metabolism
of RNA and transport. In FTLD-TDP there is a ‘clearing’ of
normal physiological TDP-43 from the nucleus with its ac-
cumulation within the cytoplasm as NCI, DN or NII. How-
ever, the precise mechanism(s) directing this pathological
change remain unclear.
Previous studies have pointed to specific interactions
between particular hnRNPs and the pathological inclu-
sions of FTLD. For example, we [9] and others [3, 23, 24]
have shown that hnRNP A3 is present in the aggregates of
dipeptide repeat proteins (DPR) in FTLD patients bearing
expansions in C9orf72 gene. Elsewhere, Gami-Patel and
colleagues reported the presence of various hnRNPs, but
especially hnRNP A1, within NCI in patients with the
Neuronal Intermediate Filament Inclusion Body Disease
form of FTLD-FUS [12].
TDP-43 is a stress responsive protein, and the TDP-43
aggregates in FTLD-TDP are thought to arise from
stress granules [6, 18, 37]. Stress granules are transient
cytoplasmic structures composed of mixed protein-RNA
complexes, formed in response to cellular stress and
believed to act as a sorting station, triaging mRNAs and
sequestering transcripts not needed for coping with the
stress [10]. Their composition and morphology varies
according to the cell and stress type, but are generated
by a reversible aggregation of prion-like core compo-
nents such as the T-cell intracellular antigen-1 (TIA-1)
and the poly A binding protein 1 (PABP1) [13] in order
to regulate mRNA metabolism and protein translation
[1, 18]. Biochemical studies have shown that TDP-43
associates with stress granules by interacting with TIA-1
[18]. Furthermore, using a yeast two-hybrid screen
against TIA-1, hnRNP E2 was reported to be present in
stress granules and processing bodies in HeLa cells, and
an interaction between hnRNP E2 and TIA-1 was dem-
onstrated by double immunofluorescence [11]. Finally, it
has been reported that TDP-43 pathological inclusions
in patients with bvFTD and FTLD-TDP pathology, and
in others with ALS, co-localise with multiple markers of
stress granules including TIA-1 [18]. Hence, it seems
likely that both TDP-43 and hnRNP-E2 can be incorpo-
rated into stress granules under stress conditions.
With this in mind, we sought possible relationships
between hnRNP E2 and the TDP-43 pathological inclu-
sions of FTLD since, because of their shared links with
stress granules, it is plausible that hnRNP E2 might be a
component of the TDP-43 pathological inclusions that
form within neuronal cell bodies (NCI) and processes
(DN). We find that hnRNP E2 immunostaining co-local-
ises with TDP-43 pathological changes, but only in patients
with SD and type C TDP-43 histology. Collectively, present
and previous [3, 9, 23, 24] data suggest that although
pathological accumulations of TDP-43 or FUS are hall-
mark characteristics of FTLD, the fundamental biological
mechanisms leading to these molecular end-points may
differ between pathological subtypes.
Materials and methods
Patients
The study consisted of 2 groups comprising 90 subjects in
total. One group had been recruited through Manchester
Brain Bank (MBB), 54 with a clinical diagnosis of FTLD
(30 males, 24 females; cases #1-54), and 10 healthy control
subjects (3 males, 7 females; cases #55-64) (Table 1). The
brains of these patients had been consecutively acquired
by MBB over the years 1986 to present. All patients were
from the North West of England and North Wales, and
tissues were obtained through appropriate consenting
procedures for the collection and use of the human brain
tissues. All patients fulfilled relevant clinical diagnostic cri-
teria [14, 25, 31], having been investigated longitudinally
within a specialist dementia clinic using the Manchester
Neuropsychological Profile (Man-NP) [35, 36] to deter-
mine and characterise the nature of their dementia.
The other group was recruited through Queens Square
Brain Bank (QSBB) and comprised 26 patients with a
clinical diagnosis of FTLD (12 males, 14 females; cases
#65-90) (Table 1). The brains of these patients had been
consecutively acquired by QSBB over the years 2004 to
present. All patients were from London and South of
England, and tissues were obtained through appropriate
consenting procedures for the collection and use of the
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Table 1 Selected clinical, neuropathological and genetic details on patients studied
case ID# MRC ID# clinical TDP subtype mutation gender PMI (h) Onset (y) Death (y) Duration (y)
1* BBN_5681 bvFTD FTLD-TDP A C9ORF72 M 74 49 58 9
2* BBN_5706 bvFTD FTLD-TDP A C9ORF72 M 28 60 68 8
3* BBN_5719 bvFTD FTLD-TDP A C9ORF72 F 74 59 64 5
4* BBN_5752 bvFTD FTLD-TDP A C9ORF72 M na 64 72 8
5 BBN_14793 bvFTD FTLD-TDP A C9ORF72 M 81 54 65 11
6 BBN_5756 FbvTD FTLD-TDP B C9ORF72 F 48 52 70 18
7* BBN_5771 FTD + MND FTLD-TDP B C9ORF72 F 50 63 65 2
8* BBN_5772 FTD + MND FTLD-TDP B C9ORF72 F 50 68 73 5
9 BBN_5691 FTD + MND FTLD-TDP B C9ORF72 M 72 60 62 2
10* BBN_5663 FTD + MND FTLD-TDP B C9ORF72 M 36 57 59 2
11* BBN_5742 PNFA FTLD-TDP A GRN V452WfsX38 M 57 66 71 5
12 BBN_10260 PNFA FTLD-TDP A GRN V452WfsX38 M 25 62 72 10
13* BBN_5660 bvFTD FTLD-TDP A GRN V452WfsX38 F 13 53 71 18
14 BBN_5773 bvFTD FTLD-TDP A GRN Q130SfsX124 M 74 66 73 7
15 BBN_5715 PNFA FTLD-TDP A GRN Q130SfsX124 F 24 63 71 8
16* BBN_5727 PNFA FTLD-TDP A GRN C31LfsX34 M 104 66 73 7
17 BBN_5718 bvFTD FTLD-TDP A GRN R493X M 35 59 66 7
18 BBN_5675 bvFTD FTLD-TDP A GRNR493X F 12 51 61 10
19 BBN_5686 bvFTD FTLD-TDP A GRN Q468X F 48 60 66 6
20 BBN_5734 bvFTD FTLD-TDP A none M 48 69 75 6
21* BBN_5685 PNFA FTLD-TDP A none M 19 68 78 10
22 BBN_5757 PNFA FTLD-TDP A none F 72 66 77 11
23 BBN_5753 bvFTD FTLD-TDP A none F 46 66 72 6
24 BBN005.28193 bvFTD FTLD-TDP A none F 144 67 72 5
25 BBN005.29059 bvFTD FTLD-TDP A none M 52 67 71 4
26 BBN_5661 FTD + MND FTLD-TDP B none M 21 43 45 2
27* BBN_5676 FTD + MND FTLD-TDP B none M na 60 68 8
28* BBN_5701 FTD + MND FTLD-TDP B none M 30 45 51 6
29* BBN_5721 FTD + MND FTLD-TDP B none M 87 58 69 11
30 BBN_5732 FTD + MND FTLD-TDP B none F 164 50 52 3
31* BBN_5764 FTD + MND FTLD-TDP B none M 110 61 65 4
32 BBN_24314 FTD + MND FTLD-TDP B none F 133 61 63 2
33 BBN005.28645 FTD + MND FTLD-TDP B none M 114 64 69 5
34 BBN_5678 SD FTLD-TDP C none M 48 54 68 14
35 BBN_5708 SD FTLD-TDP C none F 28 55 66 11
36* BBN_5720 SD FTLD-TDP C none M 59 60 75 15
37 BBN_5726 SD FTLD-TDP C none F 104 56 67 11
38 BBN_5736 SD FTLD-TDP C none F 168 70 72 2
39* BBN_5731 SD FTLD-TDP C none M 44 71 77 6
40 BBN_16418 SD FTLD-TDP C none M 29 56 68 12
41 BBN_19623 SD FTLD-TDP C none F 86 68 82 14
42 BBN005.26066 SD FTLD-TDP C none M 59 52 66 14
43 BBN005.28698 SD FTLD-TDP C none M 35 57 77 20
44 BBN_5659 bvFTD FTLD-tau MAPT exon 10 + 16 M 46 50 61 11
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Table 1 Selected clinical, neuropathological and genetic details on patients studied (Continued)
45 BBN_5696 bvFTD FTLD-tau MAPT exon 10 + 16 F 52 46 58 12
46 BBN_5699 bvFTD FTLD-tau MAPT exon 10 + 16 M 30 43 55 12
47 BBN_5717 bvFTD FTLD-tau MAPT exon 10 + 16 F 23 52 65 13
48 BBN_5744 bvFTD FTLD-tau MAPT exon 10 + 16 F 33 50 60 10
49* BBN_5733 bvFTD FTLD-tau MAPT exon 10 + 16 M 24 46 53 7
50 BBN_5760 bvFTD FTLD-tau MAPT exon 10 + 16 F 96 48 63 15
51 BBN_5763 bvFTD FTLD-tau MAPT exon 10 + 16 F 48 52 58 6
52 BBN_6081 bvFTD FTLD-tau MAPT exon 10 + 16 F 26 53 63 10
53 BBN005.29180 bvFTD FTLD-tau MAPT exon 10 + 16 F 83 60 69 9
54 BBN_5710 bvFTD FTLD-tau MAPT exon 10 + 13 M 43 65 70 5
55 BBN_3109 Control none none F 72 na 76 na
56 BBN_3124 Control none none F 44 na 82 na
57 BBN_3126 Control none none M 52 na 80 na
58* BBN_3378 Control none none F 48 na 77 na
59 BBN_3447 Control none none F 41 na 80 na
60 BBN_20608 Control none none F 130 na 76 na
61 BBN_3337 Control none none F 12 na 87 na
62* BBN_3430 Control none none M 49 na 84 na
63 BBN_25922 Control none none F 103 na 100 na
64 BBN_25974 Control none none M 93 na 91 na
65 BBN_8556 bvFTD FTLD-TDP A C9orf72 M 77 53 63 10
66 BBN_8109 PNFA FLTD-TDP A C9orf72 F 85 56 67 11
67 BBN_20082 PNFA FTLD-TDP A C9orf72 F 63 57 62 5
68 BBN007.29537 bvFTD FTDL-TDP A C9orf72 M 52 66 71 5
69 BBN007.26830 bvFTD FTLD-TDP A C9orf72 F 107 58 66 8
70 BBN_11628 bvFTD FLTD-TDP A TBK1 M 97 62 72 10
71 BBN_11698 bvFTD FTLD-TDP A none F 85 57 63 6
72 BBN_11574 bvFTD FTDL-TDP A none F 8 70 83 13
73 BBN_12507 bvFTD FTLD-TDP A none M 93 57 62 5
74 BBN007.29538 bvFTD FLTD-TDP A GRN C31LfsX34 M 29 49 55 6
75 BBN_12169 bvFTD FTLD-TDP B C9orf72 F 94 64 66 2
76 BBN_12136 MND FTLD-TDP B none M 70 67 69 2
77 BBN_11773 MND FTLD-TDP B none F 30 75 77 2
78 BBN_12451 FTD/MND FTLD-TDP B none F 46 63 67 4
79 BBN_12331 bvFTD FTLD-TDP B none F 45 63 83 20
80 BBN_12480 SD FTLD-TDP C none F 38 58 73 15
81 BBN_12524 SD FTLD-TDP C none F 84 59 73 14
82 BBN_11594 SD FTLD-TDP C none M 27 64 78 14
83 BBN_11883 SD FTLD-TDP C none M 19 64 74 10
84 BBN_8614 SD FTLD-TDP C none M 52 50 65 15
85 BBN_12300 SD FTLD-TDP C none M 71 61 66 5
86 BBN007.26814 SD FTLD-TDP C none M 76 44 67 23
87 BBN007.26851 PNFA FTLD-TDP C none F 26 77 80 3
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human brain tissues. Again, all patients fulfilled relevant
clinical diagnostic criteria [14, 25, 31] having been referred
to the Dementia Research Unit, Queen Square, London.
Of the combined 80 FTLD patients, 36 had been
clinically diagnosed with bvFTD (17 males, 19 females;
cases #1-6,13,14,17-20,23-25,44-54,65,68-75,79), 13 with
bvFTD + MND or MND alone (9 males, 4 females;
cases #7-10,26-33,76-78), 9 with PNFA (4 males, 5
females; cases #11,12,15,16,21,22,66,67,87) and 20 with
SD (12 males, 8 females; cases #34-43, 80-86, 88-90)
(Table 1). Pathologically, the FTLD group comprised 30
patients with FTLD-TDP type A (cases #1-5,11-25, 65-74),
18 with FTLD-TDP type B (cases #6-10,26-33,75-79), 21
with FTLD-TDP type C (cases #34-43,80-90), 11 with
FTLD-tau (cases #44-54) (Table 1). Furthermore, within
the FTLD group there were 16 patients with expansions
in C9orf72 (cases #1-10,65-69,75), 10 with GRN muta-
tions (cases #11-19,74), 1 patient with TBK1 mutation
(case #70), 11 patients with intronic mutations in
MAPT (cases #44-54) and 42 without known mutation
(cases #20-43,71-73,76-90) (Table 1).
Histological methods
Standard blocks of frontal (BA 8/9) and temporal
(BA21/22) lobe, the latter to include the posterior hippo-
campus at the level of the geniculate bodies, were cut
from the formalin fixed brains. Where possible, and in
order to preserve maximum antigenicity, the original
blocks taken for diagnosis were employed since these
had been cut from brains which had been fixed in for-
malin for no more than 3-6 months from the time of ac-
quisition. However, it was not possible to do this in all
instances, especially in respect of some of the more
long-standing cases (ie those acquired before 2007)
where this block was no longer available and new blocks
had to be cut from 20 cases for the purpose of this study
(see Table 1 for those cases where new blocks were cut).
Paraffin sections were cut from these blocks at a thick-
ness of 6 μm. Preliminary titration experiments were
performed at dilutions 1:100 to 1:3000 on 5 randomly
chosen cases, one from each pathological subgroup, in
order to determine optimal specific nuclear and DN/
NCI immunostaining for each antibody. When dilutions
for hnRNP E2 staining less than what was optimal for
nuclear and inclusion body staining were employed, im-
munostaining for nuclei and DN/NCI was still observed,
but less strongly so, as would be expected given the
lower antibody concentrations. Subsequently, all antibodies
were employed at these optimised dilutions (as specified
below) in a standard IHC protocol, as described previously
[7–9, 22]. The following antibodies were employed: hnRNP
E2 (also known as PCBP2) (mouse monoclonal, Santa
Cruz, 23G: sc101136, 1:100 and Novus, mouse monoclonal
H00005094-M07, 5F12 clone, 1:500), non-phosphorylated
TDP-43 (rabbit polyclonal, 10,782-2-AP antibody, Protein-
tech, Manchester, UK, 1:3000) and phosphorylated TDP
(pS409/410-2 antibody, Cosmo Biotech Ltd., Tokyo, Japan,
1:2000) and tau (mouse monoclonal, AT8, Innogenetics,
Antwerp, Belgium, 1:750) proteins. Both the Santa Cruz
and Novus hnRNP E2 antibodies are raised against recom-
binant hnRNP E2 of human origin, and on western blot-
ting detect a protein with molecular mass of around
40 kDa. For all antibodies employed, antigen unmasking
was performed by pressure cooking in citrate buffer
(pH 6.0, 10 mM) over a 30-min period to include warming
and cooling times, reaching 123 degrees Celsius for 30 s,
and >15 psi pressure.
Double immunohistochemical staining was performed
using phosphorylated TDP-43 antibody (pS409/410-2
antibody, Cosmo Biotech Ltd., Tokyo, Japan, 1:2000) and
hnRNP E2 (Novus, 5F12, 1:500) antibody to investigate
the co-localisation of the two proteins. Sections were
cut, pre-treated and incubated in primary antibody as
described above. Two Alexa Fluor secondary antibodies
(Alexa Fluor 488 and Alexa Fluor 568; Molecular
Probes, 1:300, with incubation for 1 hour at room
temperature) were used to visualise sites of protein de-
position. 4′-6-diamidino-2-phenylindol (DAPI) was used
for nuclear counterstaining.
Pathological assessment
Immunostained sections were examined microscopically
for the appearance of intracellular distribution of stain-
ing within neurones of the temporal cortex, dentate
gyrus and CA4 region of the hippocampus. These re-
gions were chosen since it was known from previous
work [7, 33] that the temporal cortex and dentate gyrus
of the hippocampus are involved in all forms of FTLD-
TDP or tau pathology in those patients with MAPT mu-
tation [29]. Moreover, the CA4 region of the hippocam-
pus was included because this is one of the principal
regions affected by DPR pathology in patients with
Table 1 Selected clinical, neuropathological and genetic details on patients studied (Continued)
88 BBN007.26876 SD FTLD-TDP C none F 31 58 72 14
89 BBN007.26890 SD FTLD-TDP C none M 40 67 76 9
90 BBN007.29539 SD FTLD-TDP C none F 25 52 65 13
PMI Post mortem delay interval, na data unavailable. Cases with asterix denote that new blocks were cut for the study from long-standing archived fixed tissues
The asterix (*) denotes cases where new tissue blocks were cut from archived samples, the original diagnostic samples no longer being available for analysis
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expansions in C9orf72 [8, 22, 23]. The degree of neur-
onal nuclear and/or cytoplasmic hnRNP E2 immuno-
staining in each region was scored semi-quantitatively
[9] at an objective magnification of ×25 (overall micro-
scope magnification of ×250) employing the following
rating scale:
0 = No staining present.
0.5 = rare (ie 1-5) cells per section showing weak
nuclear and/or cytoplasmic staining.
1 = few (1-5) cells showing weak nuclear and/or
cytoplasmic staining per ×250 microscope field.
2 = moderate number (5-10) cells showing moderate
nuclear and/or cytoplasmic staining per ×250
microscope field.
3 = more than 10 cells showing strong nuclear and/or
cytoplasmic staining per ×250 microscope field.
The severity of hnRNP E2-immunoreactive, and TDP-
43-immunoreactive, inclusion body immunostaining (ie
NCI and DN) in frontal and temporal cortex, and in
granule cells of the dentate gyrus of the hippocampus,
was separately graded at an objective magnification of
×25 (overall microscope magnification of ×250), employ-
ing the following rating scale:
0 = no inclusions present.
0.5 = rare (ie 1-5 inclusions per section).
1 = few (ie 1-5 inclusions per ×250 microscope field).
2 = moderate (ie 5-10 inclusions per ×250 microscope
field).
3 = many (ie 10-50 inclusions per ×250 microscope field).
4 = very many (ie more than 50 inclusions per ×250
microscope field).
Scoring of staining was performed by a single observer
(DMAM) blinded to clinical, histopathological and genetic
status. Previous use of this particular scoring system has
shown robust agreement in assessments when employed
by both highly and lesser experienced observers [9].
Double immunolabelled sections were viewed with a
Leica TCS4D confocal microscope using a 3-channel
scan head and argon/krypton laser.
Statistical analysis
Rating data was entered into an excel spreadsheet and
analyzed using Statistical Package for Social Sciences
(SPSS) software (version 17.0). The 80 FTLD patients
were stratified according to genetic and pathological
subtype for statistical analysis of the effect of each muta-
tion and underlying pathology on the degree and pattern
of hnRNP E2 staining. Comparisons of semi-quantitative
scores for the intensity of neuronal hnRNP E2 immuno-
staining in nucleus and cytoplasm of neurones of the
frontal and temporal cortex, and dentate gyrus of the
hippocampus, with respect to pathological type or gen-
etic mutation, were performed using Kruskal-Wallis test
with post-hoc Mann-Whitney test where Kruskal-Wallis
yielded a significant difference between antibody staining
scores. Comparisons of semi-quantitative scores for the
severity of hnRNP E2- and TDP-43-immunoreactive
inclusions in frontal and temporal cortex, and dentate
gyrus of the hippocampus, with respect to pathological
subtype, were also performed using Kruskal-Wallis test.
Comparison of scores for the severity of hnRNP E2- and
TDP-43-immunoreactive inclusions in the same cases
was made using Wilcoxon matched pairs test. Group
comparisons of age at onset, age at death, post mortem
delay interval and duration of illness were made using
ANOVA with post hoc Tukey test. In all instances, sig-
nificance levels were set at p < 0.05.
Results
Demographic comparisons
Comparison of the 4 FTLD pathology patient groups
showed significant differences in mean age at onset of
disease (F3,76 = 4.9, p = 0.004), mean age at death
(F3,76 = 7.0, p < 0.001) and duration of illness did differ
(F3,76 = 8.3, p < 0.001). Patients with FTLD-tau had an
earlier age at onset than those with FTLD-TDP type A
(p = 0.002), type B (p = 0.016) and type C (p = 0.012)
pathology (Table 2) and an earlier age at death than
those with FTLD-TDP type A (p = 0.014) and type C
(p < 0.001) pathology, but not those with FTLD-TDP
type B (p = 0.449) pathology. None of the 3 FTLD-TDP
groups differed from each other in terms of age at onset,
though patients with FTLD-TDP type B pathology died
at an earlier age than those with FTLD-TDP type C
pathology (p = 0.015). Patients with FTLD-TDP type B
had a shorter disease duration than those with FTLD-
TDP type C (p = 0.001) and those with FTLD-tau
(p = 0.040); those with FTLD-TDP type A pathology also
had a shorter disease duration than those with FTLD-
TDP type C (p = 0.006), but there were no other differ-
ences between the other sub-types (Table 2). The healthy
control group was also significantly older at death
(p < 0.001) than each of the FTLD subgroups (Table 2).
Comparison of the 4 FTLD genetic patient groups also
showed significant differences in mean age at onset of
disease (F3,75 = 5.1, p = 0.003) and mean age at death
(F3,75 = 5.0, p = 0.003), though duration of illness did
not differ significantly (F3,75 = 1.2, p = 0.329). Patients
with MAPT mutation had an earlier age at onset than
those with GRN mutation (p = 0.050) and those without
known mutation (p = 0.001), but not those with C9orf72
expansion (p = 0.088). The other groups did not signifi-
cantly differ from each other. Mean age at death was
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significantly earlier in MAPT than the no mutation
group (p = 0.002), but otherwise there were no signifi-
cant differences between all other groups (Table 2).
There were no significant differences between mean
post mortem intervals for each pathological (F4,83 = 1.0,
p = 0.401) or genetic (F4,73 = 1.6, p = 0.181) group (see
Table 2), nor were there any significant correlations
between each pathological measure and post mortem
interval (p = 0.351-0.993).
TDP-43 immunostaining
TDP-43- and tau-immunostaining was employed to clas-
sify the 80 FTLD patients into their respective patho-
logical subgroups (FTLD-TDP subtypes A, B or C and
FTLD-tau) according to the form and distribution of the
TDP-43 or tau-immunoreactive inclusions (NCI, DN)
present (see [19] for criteria). Median scores (with inter-
quartile range) from TDP-43 immunostaining of patho-
logical inclusions and neuronal nuclei and cytoplasm,
derived from semi-quantitative scoring are shown in
Table 3. As expected, given the inclusion of FTLD-tau
group, the degree of TDP-43 inclusion body immuno-
staining (irrespective of whether these were in the form
of NCI or DN, or both) differed between the 4 FTLD
pathological groups in both the frontal (χ2 = 34.1,
p < 0.001) and temporal (χ2 = 36.8, p < 0.001) cortex,
and in the dentate gyrus (χ2 = 35.3, p < 0.001) with all 3
FTLD-TDP subtypes differing significantly from FTLD-
tau group (p < 0.001 in every instance). However, there
were no significant differences in the overall degree of
TDP-43 immunostaining between FTLD-TDP type A,
type B or type C subgroups.
hnRNP E2 immunostaining
When using Santa Cruz hnRNP E2 antibody, 58/80
FTLD patients, and 8/10 controls, showed a variable
level of cellular staining within nerve cells of the frontal
and temporal cortex, and in granule cells of the dentate
Table 2 Mean +/− SD age at onset, death and duration of illness, and gender composition, for each neuropathological and genetic
subgroup of patients. Mean +/− SD and median (in parentheses) post mortem delay interval (PMI) is also presented for each group
Group M/F Onset (y) Death (y) Duration (y) PMI (h)
FTLD-TDP type A (n = 30) 17/13 60.7 ± 6.2 68.7 ± 6.1 8.0 ± 3.0 59.5 ± 33.3 (57)
FTLD-TDP type B (n = 18) 9/9 59.7 ± 8.0 65.2 ± 9.2 5.6 ± 5.5 70.6 ± 40.6 (50)
FTLD-TDP type C (n = 21) 12/9 59.7 ± 7.9 71.8 ± 5.3 12.1 ± 5.1 54.7 ± 35.1 (44)
FTLD-tau (n = 11) 4/7 51.4 ± 6.4 61.4 ± 5.4 10.0 ± 3.1 45.8 ± 24.0 (44)
FTLD C9orf72 expansion (n = 16) 8/8 58.8 ± 5.3 65.7 ± 4.4 6.9 ± 4.6 66.1 ± 21.9 (72)
FTLD GRN mutation (n = 10) 6/4 59.5 ± 6.4 67.9 ± 5.9 8.4 ± 3.7 42.1 ± 29.2 (32)
FTLD No mutation (n = 42) 23/19 60.7 ± 7.9 70.0 ± 8.1 9.3 ± 5.5 62.6 ± 40.2 (48)
FTLD MAPT mutation (n = 11) 4/7 51.4 ± 6.4 61.4 ± 5.4 10.0 ± 3.1 45.8 ± 24.0 (44)
FTLD TBK1 mutation (n = 1) 1/0 62 72 10 97
Healthy Controls (n = 10) 3/7 na 83.3 ± 7.6 na 64.4 ± 35.0 (50.5)
Table 3 Median values with interquartile range for hnRNP E2
immunostaining of pathological inclusions, neuronal nuclei and
cytoplasm in frontal and temporal cortex, and dentate gyrus of
hippocampus, for each pathological subgroup
Frontal cortex
Group E2 inclusions E2 nucleus E2 cytoplasm
FTLD-TDP type A 0 (0-0) 1 (0-1) 1 (0-2)
FTLD-TDP type B 0 (0-0) 0.75 (0-1.25) 1 (0-1.25)
FTLD-TDP type C 1 (1-2) 1 (0-3) 1 (0.5-2)
FTLD-tau 0 (0-0) 2 (1-2) 1 (0-2)
Healthy Controls 0 (0-0) 1.5 (0-3) 1.5 (0-2.25)
Temporal cortex
E2 inclusions E2 nucleus E2 cytoplasm
FTLD-TDP type A 0 (0-0) 1 (0-1) 1 (0-2)
FTLD-TDP type B 0 (0-0) 0.75 (0-1.25) 1 (0-1.25)
FTLD-TDP type C 1 (1-3) 2 (0-3) 2 (0.5-3)
FTLD-tau 0 (0-0) 2 (1-2) 1 (0-2)
Healthy Controls 0 (0-0) 1.5 (0-3) 1.5 (0-2.25)
Dentate Gyrus
E2 inclusions E2 nucleus E2 cytoplasm
FTLD-TDP type A 0 (0-0) 1 (0-1) 1 (0-2)
FTLD-TDP type B 0 (0-0) 0.75 (0-2) 1 (0-2)
FTLD-TDP type C 2 (0-3) 2 (0-3) 2 (0-3)
FTLD-tau 0 (0-0) 1 (0-3) 1 (0-2)
Healthy Controls 0 (0-0) 1.5 (0-3) 1.5 (0-2.25)
TDP-43 inclusions
Frontal cortex Temporal cortex Dentate Gyrus
FTLD-TDP type A 3 (2-3) 3 (2-3) 1 (1-1.25)
FTLD-TDP type B 2 (2-3) 2 (2-3) 2 (1-3)
FTLD-TDP type C 2 (2-3) 3 (2-3) 3 (2-3)
FTLD-tau 0 (0-0) 0 (0-0) 0 (0-0)
Healthy Controls 0 (0-0) 0 (0-0) 0 (0-0)
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gyrus of hippocampus. When present, this was usually
observed in both nucleus and cytoplasm, and ranged in
intensity from very weak to strong. Conversely, 22 FTLD
patients and 2 controls showed no nuclear or cytoplas-
mic staining at all in any region examined. Twenty of
these cases had been stored for long periods (in excess
of 10 years) in formalin fixation before blocks had been
taken for this study, whereas the brains of those cases
based on diagnostic blocks had been stored for a shorter
time in formalin fixation before blocking (3-6 months),
and all these, except 4 cases, showed variable degrees of
nuclear and cytoplasmic staining. There did not appear
to be any pathological or genetic group preference for
presence/absence of this kind of staining. Hence, some
degree of positive (nuclear or cytoplasmic, or both)
staining was seen in 22/30 (73%) patients with FTLD-
TDP type A histology, 11/18 (61%) patients with FTLD-
TDP type B, 16/21 (76%) patients with FTLD-TDP type
C, 9/11 (81%) patients with FTLD-tau and 8/10 (80%)
controls. According to FTLD genetics, some positive
degree of positive staining was seen in 9/16 (56%) patients
with C9orf72 expansion, 7/10 (70%) patients with GRN
mutation, 32/42 (76%) patients with no mutation and 9/11
(80%) patients with MAPT mutation. There were no
significant differences between the proportions of FTLD
patients showing some degree of hnRNP E2 immunostain-
ing when stratified either by pathological (χ2 = 2.09,
p = 0.718) or genetic (χ2 = 1.98, p = 0.577) groupings.
Median scores (with interquartile range) from hnRNP
E2 immunostaining of pathological inclusions and neur-
onal nuclei and cytoplasm, derived from semi-quantitative
scoring, for each of the pathological groups are shown in
Table 3. Statistical analysis showed no significant differ-
ences in scores for nuclear and cytoplasmic hnRNP E2
staining in frontal cortex (χ2 = 5.8, p = 0.120 and χ2 = 2.5,
p = 0.479, respectively), temporal cortex (χ2 = 6.7,
p = 0.080 and χ2 = 3.6, p = 0.312, respectively) or dentate
gyrus (χ2 = 5.7, p = 0.128 and χ2 = 2.7, p = 0.444, respect-
ively). Similarly, no significant differences in scores for nu-
clear and cytoplasmic hnRNP E2 staining in the 4 genetic
groups were seen in frontal cortex (χ2 = 4.0, p = 0.400 and
χ2 = 1.1, p = 0.891, respectively), temporal cortex
(χ2 = 3.6, p = 0.463 and χ2 = 1.1, p = 0.889, respectively)
or dentate gyrus (χ2 = 4.5, p = 0.338 and χ2 = 1.2,
p = 0.882, respectively).
DN with morphology akin to that seen on TDP-43 im-
munostaining (Fig. 1a and b) were seen on hnRNP E2 im-
munostaining (Fig. 1d and e) in the frontal (Fig. 1a and c)
and temporal (Fig. 1b and e) cortex of 15/21 FTLD-TDP
type C cases. In the same cases similar rounded, solid-
appearing NCI seen on TDP-43 immunostaining in den-
tate gyrus granule cells (Fig. 1c) were also seen on hnRNP
E2 immunostaining (Fig. 1f). Only FTLD-TDP type C
cases had pathological inclusions labelled by hnRNP
E2.There was no immunolabelling by hnRNP E2 of TDP-
43 or tau inclusions in FTLD-TDP type A or type B cases
or those with FTLD-tau. Interestingly, there was no appar-
ent loss of physiological immunostaining of the nucleus
for hnRNP E2 in those cells of the dentate gyrus bearing
NCI (Fig. 1f), in contrast to that seen with TDP-43 where
there was loss of normal nuclear staining in those cells
containing TDP-43 immunoreactive NCI (Fig. 1c).
There were no clinical or neuropathological differ-
ences between the 15 hnRNP E2 positive cases (cases
#37,40-43,81-90) and the 6 hnRNP E2 negative cases
(cases #34-36,38,39,80). Moreover, there were no differ-
ences in age at onset (p = 0.542), age at death (p = 0.966),
duration of illness (p = 0.405) or post mortem interval
a b c
d e f
Fig. 1 Dystrophic neurites seen on TDP-43 immunostaining (arrowed in a and b) were similarly seen on hnRNP E2 immunostaining
(arrowed in d and e), in frontal (a and d) and temporal (b and e) cortex in FTLD-TDP type C cases. In the same cases rounded, solid-
appearing NCI (arrowed) seen on TDP-43 immunostaining in dentate gyrus granule cells (c) were also seen in TDP-43 immunostaining (f).
Immunoperoxidase-haematoxylin; microscope magnification ×400
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(p = 0.285) between the 15 positive and 6 negative cases.
The only difference between the two groups was that the
negative FTLD-TDP type C cases employed tissue blocks
that had been newly cut for this study from long-standing
(before 2007) archived fixed tissues as the original diag-
nostic blocks were no longer available for study. All other
cases employed the original diagnostic blocks cut after
3-6 months fixation. Furthermore, within those FTLD
cases bearing expansions in C9orf72 gene, there was no
immunostaining of the TDP-43-negative, p62-positive
DPR inclusions within neurones of frontal and temporal
cortex, or dentate gyrus granule cells and CA4 neurones
of the hippocampus.
Consequently, semi-quantitative analysis within 5
pathological groups showed a significant difference in
scores for hnRNP E2 positive inclusions in the frontal
cortex (χ2 = 46.6, p < 0.001), temporal cortex (χ2 = 50.6,
p < 0.001) and dentate gyrus (χ2 = 50.7, p < 0.001), with
the number of inclusions in both areas being signifi-
cantly different in FTLD-TDP type C cases than all other
pathological subtypes (p < 0.001 in every instance). This
result would be expected given the observations that
only in FTLD-TDP type C cases were there pathological
inclusions immunostained by hnRNP E2.
The results of immunostaining with the Novus hnRNP
E2 antibody appeared broadly similar to those obtained
with Santa Cruz antibody on all cases of FTLD-TDP type
C, and selected cases of the other pathological subtypes,
where both antibodies were employed, both with respect to
the intensity of neuronal staining and severity of inclusion
body staining. Comparison of semi-quantitative scores for
the intensity of nuclear and cytoplasmic staining, and inclu-
sion body staining, on all 21 cases of FTLD-TDP type C
showed that Novus antibody immunostained nuclei less in-
tensely than Santa Cruz antibody (frontal cortex p = 0.008,
temporal cortex p = 0.005; dentate gyrus p = 0.005), but
there were no significant differences between the antibodies
for level of cytoplasmic staining (p = 0.617, p = 0.120 and
p = 0.104, respectively). There were no significant differ-
ences between scores for inclusion body staining with both
antibodies for frontal cortex (p = 0.054) and temporal cor-
tex (p = 0.655) with only a trend for scores in dentate gyrus
to be greater (p = 0.023) for Novus antibody.
In general, the number of DN or NCI visualised on
hnRNP E2 immunostaining appeared fewer than those
seen in TDP-43 immunostaining (compare Fig. 1a with d,
and b with e and c with f). Indeed, comparison of scores
for TDP-43- and hnRNP E2- immunostaining of DN in
FTLD-TDP type C cases showed that the number of
DN immunostained for hnRNP E2 was significantly less
than that immunostained for TDP-43 in frontal cortex
(p = 0.004), temporal cortex p = 0.002) and dentate gyrus
(p = 0.010). Consequently, double immunofluorescence la-
belling for TDP-43 and hnRNP E2 (using either the Santa
Cruz or the Novus antibody) was performed on selected
cases of FTLD-TDP type C and showed a good degree of
colocalisation between the two proteins (Fig. 2).
Discussion
In the present study, we have investigated the pattern of
hnRNP E2 immunostaining across a range of clinical,
pathological and genetic forms of FTLD. We found no sig-
nificant changes in the amount, or intraneuronal distribu-
tion pattern, of neuronal hnRNP E2 immunostaining in
any of the clinical, pathological or genetic FTLD sub-
groups. On the other hand, a strong immunostaining of
DN and NCI, resembling that seen on TDP-43 immuno-
staining, was seen in 15/21 cases of SD with FTLD-TDP
type C histology. No immunostaining of NCI, DN or NII
for hnRNP E2 was seen in any of the other histological
forms of FTLD-TDP, or in cases of FTLD-tau. However, it
is not clear why only 15/21 cases of SD showed hnRNP
E2-immunoreactive DN and NCI, despite there being
plentiful TDP-43-immunoreactive DN and NCI present in
the 6 other negatively staining cases. Long term storage of
tissues in formalin rather than variations in clinical or
pathological features, or differences in post mortem inter-
val, is most likely responsible for the lack of hnRNP E2
immunostaining of DN and NCI, since it was necessary to
prepare new samples from these 6 cases from archived
fixed tissues as original freshly cut tissue blocks were no
longer available for study. The complete lack of neuronal
nuclear or cytoplasmic hnRNP E2 immunostaining in
these same 6 cases supports this interpretation.
Interestingly, while incorporation of TDP-43 into NCI
and DN was associated with loss of normal physiological
TDP-43 immunostaining, there was no apparent loss of
nuclear hnRNP E2 immunostaining in those cells of the
dentate gyrus of the hippocampus containing hnRNP E2
immunoreactive NCI. Although, by analogy with TDP-43,
this loss might have been anticipated to have occurred, this
cannot be necessarily assumed to be the case, since while
some hnRNP E2 protein will be binding to TDP inclusions
during the formation/evolution of NCI (and DN), at the
same time the remainder will still be available to participate
in its normal physiological role (and generating nuclear
staining) up until the time when the cell dies. It therefore
cannot be assumed that all hnRNP E2 protein will be mis-
localised into the cytoplasm, as is the case with TDP-43.
Present data therefore indicate an association between
hnRNP E2 and TDP-43 pathology but only in this
pathological form of FTLD. Indeed, double labelling im-
munofluorescence showed that most TDP-43 immuno-
reactive DN were immunoreactive for hnRNP E2
protein. In a previous study [9], we showed that DN and
NCI in SD did not contain other hnRNPs such as
hnRNP A1, A2/B1 or A3 suggesting that incorporation
of hnRNP E2 into DN is not simply due to a passive
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recruitment of hnRNP E2 protein, along with other
hnRNPs, into the aggregating protein conglomerate. It is
not clear why co-localization was not complete, but this
again could be due to technical reasons such as antigen
preservation or accessibility. Alternatively, it might indi-
cate that hnRNP E2 protein is incorporated into pre-
existing TDP-43 pathological inclusions at later points in
time, with those inclusions that are hnRNP E2 negative
not having had sufficient time to accrue enough hnRNP
E2 protein to be detectable by immunohistochemistry.
The results of this study imply an important role for
hnRNP E2 in the pathogenesis of SD. hnRNP E1 and E2
are the most highly expressed and well characterised iso-
forms of hnRNP E proteins in human tissues with 89%
amino acid homology. They belong to the hnRNP K pro-
tein family and have a triple hnRNP K (KH) domain, des-
ignated KH1, KH2 and KH3, through which they can bind
both poly(rC) regions and low rC mRNAs [20, 27, 28].
They can shuttle between nucleus and cytoplasm and par-
ticipate in the regulation of mRNA stability and translation
[20, 27]. It is believed that hnRNP E1 is encoded by an
intronless gene that is a product of a retrotransposition
event of a fully processed minor isoform of hnRNP E2
[21]. Each of the KH domains is able to interact independ-
ently with a target RNA sequence which gives this protein
a potentially high number of complex specific RNA inter-
actions. Woolaway and colleagues demonstrated that de-
pletion of either hnRNP E1 or hnRNP E2 lead to increased
production of HIV-1 structural proteins, whereas overex-
pression of hnRNP E1, but not hnRNP E2, inhibited ex-
pression of Rev.-dependent RNAs encoding gp120 and
p24 [38]. Other work has demonstrated a higher affinity of
hnRNP E1 for hnRNP D than hnRNP E2 [17], and hnRNP
E1 and hnRNP E2 have differential responses to hypoxic
stress [39]. Both hnRNP E1 and hnRNP E2 can regulate
BC200 RNA-mediated translation inhibition but not
Fig. 2 Immunofluorescence for TDP43 (red) and hnRNP E2 (green) in the temporal cortex (a,b) and dentate gyrus of the hippocampus (c,d) of
FTLD cases. TDP43 and hnRNP E2 (merge) co-localize in both neuropil threads (a,b) and neuronal inclusions (c,d). Microscope magnification: ×200
(a,c); ×630 (c,d).
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through the same control mechanism [16]. Therefore,
despite the high degree of sequence similarities between
hnRNP E1 and hnRNP E2 isoforms, they each have dis-
tinct non-redundant cellular functions.
Little is known concerning any specific role for hnRNP
E2 within the nervous system in health or neurodegener-
ative disease, beyond that of control of mRNA stability
and mRNA translation. Broderick and coworkers reported
that hnRNP E2 can bind to exon 10 of MAPT and acti-
vate/regulate alternative splicing [4]. Mis-splicing of
exon 10 is a cause of that form of FTLD-tau, known as
Frontotemporal Dementia with parkinsonism linked to
chromosome 17 (FTDP-17) in which there is increased
use of this splice site leading to an imbalance in the ra-
tio of 3-repeat and 4-repeat tau isoforms, in favour of
4-repeat tau, with aggregation of the excess 4-repeat
tau into neurofibrillary tangle-like structures [15, 29].
In the present study we investigated 11 cases of FTDP-
17 associated with intronic mutations affecting exon
10, but did not find any changes in neuronal hnRNP E2
immunoreactivity or binding of hnRNP E2 to aggre-
gated tau, implying that the functional disturbances
leading to increased splicing of exon 10 in this form of
FTLD are not mediated by changes in hnRNP E2. Such
a conclusion would be supported by the lack of tauopathy
in patients with SD where hnRNP E2 pathological changes
are associated with TDP-43 proteinopathy instead.
To our knowledge, there have been no previous re-
ports documenting any direct functional or pathological
association between hnRNP E2 protein and TDP-43, and
the mechanism leading to binding of hnRNP E2 to DN
and NCI in patients with SD remains unclear. It is plaus-
ible that this scenario could underpin the presence of
hnRNP E2 and TDP-43 in DN in patients with SD.
However, it is not clear why, in the present report,
hnRNP E2 was not also seen in the TDP-43 pathological
inclusions of other forms of FTLD-TDP (ie FTLD-TDP
types A and B) when these have also been shown to con-
tain markers of stress granules such as TIA-1 [18].The
absence of hnRNP E2 in the TDP-43 pathological inclu-
sions of other forms of FTLD-TDP points to a disease
mechanism which is specific to patients with SD and
FTLD-TDP type C pathology, and one not shared by
other forms of FTLD-TDP despite all pathological forms
being linked by the same pathological ‘end product’.
Conclusions
In the present study we have shown that a high propor-
tion of TDP-43-positive DN in patients with SD contain
hnRNP E2 protein; no other histological forms of FTLD-
TDP showed this association, nor were NCI in FTLD-
tau hnRNP E2-immunoreactive despite evidence that
hnRNP E2 may function as a modulator of alternative
splicing of MAPT. The association between hnRNP E2
and TDP-43 in DN in SD, when taken in conjunction with
previous findings showing specific interactions between
hnRNP A1 and FUS-positive NCI [12] and hnRNP A3 and
DPR in C9orf72 expansion carriers [3, 9, 23, 24], suggests
that specific changes in different hnRNPs might underlie
each pathological form of FTLD. The exact nature of how
these proteins (hnRNP E2, TDP) might interact is outside
the scope of the present study and requires further work,
employing expression studies, western blotting or pull-
down methodologies, for example, to support the present
argument that an increase in hnRNP E2 protein in NCI is
specific to FTLD-TDP type C.
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